24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
MEGESLIEVA 160MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | MEGESLIEVA 160MG |
|---|---|
| Composition | Megestrol Tablets IP 160mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (3 x 10) |
| Country of Origin | India |
MEGESLIEVA 160MG (Megestrol Tablets IP 160mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
MEGESLIEVA 160 MG (Megestrol Tablets IP 160 mg) is a prescription medication containing Megestrol Acetate 160 mg, a synthetic progestin widely used in oncology and supportive care. It is commonly prescribed for the management of certain hormone-sensitive cancers and for the treatment of loss of appetite (anorexia), significant weight loss, and cancer-related cachexia in patients requiring nutritional support.
Megestrol Acetate belongs to a class of medicines known as progestational agents. It works by influencing hormone activity within the body and helping regulate processes associated with appetite, metabolism, and cell growth. In oncology, Megestrol may be used as part of treatment strategies for selected hormone-responsive cancers, while in supportive care it is frequently prescribed to stimulate appetite and promote weight gain in patients experiencing unintended weight loss.
Cancer and chronic illnesses can often lead to poor appetite, nutritional deficiencies, and muscle wasting, which may affect overall quality of life and treatment outcomes. MEGESLIEVA 160 MG helps improve appetite, increase food intake, and support weight maintenance, making it an important supportive therapy for many patients undergoing cancer treatment or living with chronic medical conditions.
MEGESLIEVA 160 MG is commonly prescribed for:
The medicine may be prescribed alone or as part of a broader treatment plan depending on the patient's medical condition and therapeutic goals.
Manufactured according to stringent pharmaceutical quality standards, MEGESLIEVA 160 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Megestrol therapy should undergo regular medical evaluations to monitor treatment response, body weight, nutritional status, and overall health.
Due to its established role in appetite stimulation and supportive oncology care, MEGESLIEVA 160 MG remains an important treatment option in modern clinical practice.
MEGESLIEVA 160 MG (Megestrol Tablets IP 160 mg) is used in supportive care, nutritional management, and selected hormone-sensitive cancers.
The medicine is widely used to improve appetite in patients experiencing reduced food intake.
Megestrol helps support weight gain and nutritional recovery in cancer patients.
The medicine may be prescribed to manage severe weight loss associated with advanced cancer.
Doctors may include Megestrol as part of comprehensive nutritional management plans.
In selected cases, the medicine may be used as part of hormone therapy.
Megestrol may be prescribed for certain patients with hormone-responsive endometrial cancer.
The medicine supports quality of life and nutritional well-being in patients requiring ongoing medical care.
Megestrol Acetate belongs to a class of medicines known as Progestational Agents.
MEGESLIEVA works by:
Its appetite-enhancing and hormonal effects make it valuable in supportive oncology and nutritional care.
Like all medicines, MEGESLIEVA 160 MG may cause side effects in some patients. Most side effects are manageable under medical supervision.
Many patients notice a significant increase in appetite during treatment.
Weight gain is a common and often desired therapeutic effect.
Swelling in the hands, feet, or ankles may occur.
Some patients may experience tiredness or weakness.
Mild nausea may develop during treatment.
Headaches may occur in some individuals.
The medicine may affect blood glucose control in certain patients.
Occasional emotional or mood-related changes may occur.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of MEGESLIEVA 160 MG (Megestrol Tablets IP 160 mg) should always be determined by a qualified healthcare professional.
The dosage depends on the reason for treatment.
Patient weight and nutritional status may influence dosing decisions.
Dosage may vary depending on whether the medicine is used for appetite stimulation or hormone therapy.
Doctors may adjust dosage according to clinical response.
Existing health conditions may affect treatment planning.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant women should not use this medicine unless specifically advised by a healthcare professional.
It is commonly used to stimulate appetite, manage cancer-related weight loss, and support nutritional recovery. It may also be used in selected hormone-sensitive cancers.
Megestrol Acetate is a synthetic progestin that helps improve appetite, support weight gain, and influence hormone-responsive tissues.
Yes. One of its primary therapeutic uses is to increase appetite and support healthy weight gain.
It may be used in selected hormone-sensitive cancers, but it is also widely used as supportive care for patients experiencing appetite loss and weight loss.
Patients with diabetes should consult their healthcare provider, as the medicine may affect blood sugar levels.
Yes. Swelling and fluid retention may occur in some patients during treatment.
Yes. Doctors may monitor body weight, nutritional status, blood sugar levels, and overall treatment response.
Yes. This medicine should only be used under the guidance of qualified healthcare professionals to ensure